Enanta's COVID-19 Treatment Shows Favorable Action In Healthy Participants

  • Enanta Pharmaceuticals Inc ENTA has announced topline data from a Phase 1 study of EDP-235 in healthy adult subjects. 
  • EDP-235, a coronavirus 3CL protease inhibitor, is designed to be a once-daily, oral antiviral treatment for COVID-19. 
  • Data from the Phase 1 study demonstrated favorable safety, tolerability, and pharmacokinetics with strong exposure multiples over the EC90.
  • Read Next: Safety Signals Force Enanta To Stop EDP-721 HBV Program.
  • EDP-235 was generally safe and well-tolerated up to a once-daily dose of 400mg, which provided plasma drug levels that were 6-fold and 12-fold over the plasma protein adjusted EC90 for the Alpha variant and the Delta variant, respectively. 
  • Moreover, EDP-235 is projected to have four times higher drug levels in lung tissue than plasma, driving exposure to 24-fold and 48-fold for the respective variants.
  • Enanta is moving forward with the clinical development of EDP-235, targeting a fourth quarter initiation of a Phase 2 study exploring doses of 200mg and 400mg once-daily, pending review with the FDA.
  • Price Action: ENTA shares closed at $49.70 on Thursday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareSmall CapGeneralBriefsCOVID-19 Coronavirus
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!